Your search for ‘Spruson & Ferguson’ returned 1,282 results

In May, we reported that the Australian Patent Office had issued a proposal to change certain official fees with effect from 1 August 2010.

Gene-based pharmaceuticals, namely interfering RNA compositions, now represent patentable subject matter in Australia.

In December 2005 the World Trade Organisation (WTO) members decided to transform a previously temporary waiver into a permanent amendment of the Trade Related Aspects of Intellectual Property (TRIPS) Agreement, which sets out agreed standards for national intellectual property systems. The waiver seeks to improve access to patented medicines for poorer countries.

When registering an ".au" domain name, you are required to prove that you have an Australian presence.

A look at how Dyson has been using Australia's innovation patent system as a part of its global strategy.

Article discusses how patents and patent applications are treated very differently in Indonesia.

This article considers whether change in NZ IP policy direction is likely, depending on which party emerges victorious.

A recent case provides a textbook example of how not to create a competitive start-up.

The trademark, for use with printed materials, educational services, and scientific services, was refused registration.

The program provides an alternative to filing a formal appeal during prosecution of a US patent application.

PTE provisions in Australia have been the subject of an extensive review, but the final report will not be released soon.

The deal brokered between the EPO and the Cambodian government was announced on 23 January 2017.

The PPH Improvement Initiative aims to reduce the average response time from examiners to applicants.

An initial PPH pilot programme has commenced between the Japan Patent Office and the Indian Patent Office for 3 years.

Arguably, the opening of the Indian economy and India's Patents (Amendment) Act 2005 has had a most significant impact in the area of pharmaceuticals. With the new regime, the $8 billion Indian pharmaceutical industry has been forced to adapt and recast its business models.

These additional requirements are meant to limit foreign applicants from requesting expedited patent examinations.

This system is part of the government's efforts to reduce trademark and copyright counterfeits by temporary suspension.